The estimated Net Worth of Fund, L.P.Czirr James C10 X... is at least $17.2 Миллион dollars as of 2 August 2021. Fund X owns over 10,000 units of Galectin Therapeutics Inc stock worth over $17,122,096 and over the last 4 years Fund sold GALT stock worth over $97,600.
Fund has made over 3 trades of the Galectin Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Fund sold 10,000 units of GALT stock worth $32,500 on 2 August 2021.
The largest trade Fund's ever made was selling 10,000 units of Galectin Therapeutics Inc stock on 2 August 2021 worth over $32,500. On average, Fund trades about 10,000 units every 98 days since 2020. As of 2 August 2021 Fund still owns at least 6,248,940 units of Galectin Therapeutics Inc stock.
You can see the complete history of Fund X stock trades at the bottom of the page.
Over the last 14 years, insiders at Galectin Therapeutics Inc have traded over $21,823,082 worth of Galectin Therapeutics Inc stock and bought 5,077,107 units worth $21,362,250 . The most active insiders traders include Richard E Uihlein, James C Czirr и Fund, L.P.10 X Capital Mana.... On average, Galectin Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $226,012. The most recent stock trade was executed by Richard A. Jr. Zordani on 22 August 2024, trading 3,500 units of GALT stock currently worth $8,050.
galectin therapeutics (nasdaq: galt) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. drug candidates based on the company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. we use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. we focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. our strategy is to establish clinical development approaches that add value to the company in the shortest time possible, and to seek partners as the program advances and requires much
Galectin Therapeutics Inc executives and other stock owners filed with the SEC include: